Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Aligos Therapeutics (ALGS) FCF Margin (2021 - 2025)

Aligos Therapeutics' FCF Margin history spans 5 years, with the latest figure at 12866.86% for Q4 2025.

  • For Q4 2025, FCF Margin fell 1230920.0% year-over-year to 12866.86%; the TTM value through Dec 2025 reached 3774.15%, down 249354.0%, while the annual FY2025 figure was 3774.15%, 153452.0% down from the prior year.
  • FCF Margin reached 12866.86% in Q4 2025 per ALGS's latest filing, down from 3285.43% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 121.33% in Q4 2022 to a low of 15995.71% in Q1 2023.
  • Average FCF Margin over 5 years is 3769.56%, with a median of 1632.44% recorded in 2021.
  • Peak YoY movement for FCF Margin: tumbled -1518090bps in 2023, then surged 1271819bps in 2024.
  • A 5-year view of FCF Margin shows it stood at 10304.09% in 2021, then soared by 99bps to 121.33% in 2022, then tumbled by -830bps to 1127.82% in 2023, then skyrocketed by 51bps to 557.67% in 2024, then crashed by -2207bps to 12866.86% in 2025.
  • Per Business Quant, the three most recent readings for ALGS's FCF Margin are 12866.86% (Q4 2025), 3285.43% (Q3 2025), and 1606.63% (Q2 2025).